Trade CareDx Inc - CDNA CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.21
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022262 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.01)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022262 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.01)

Key Stats

• Prev. Close: 63.58
• Open: 62.7
• 1-Year Change: 321.65%
• Day's Range: 62.7 - 64.74

Trade CareDx Inc - CDNA

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. It also has a collaborative research agreement with Eledon Pharmaceuticals, Inc. to use AlloSure for assessing the efficacy of Eledon''s investigational AT-1501 in the prevention of rejection in upcoming renal transplantation trials. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.